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Abstract
Background: Despite demonstrated efficacy, acceptance of selective estrogen receptor modulators (SERMs), such
as tamoxifen, for breast cancer risk reduction remains low. Delivering SERMs via local transdermal therapy (LTT)
could significantly reduce systemic effects and therefore may increase acceptance. We aim to assess women’s
knowledge of breast cancer prevention medications and views on LTT of SERMs.
Methods: Focus groups were conducted with healthy women identified through the comprehensive breast center
of a large urban cancer institution. Group discussions covered risk perceptions, knowledge of and concerns about
risk reducing medications. Participants reported their perceived risk for breast cancer (average, below/above average),
preference for SERMs in a pill or gel form, risk factors, and prior physician recommendations regarding risk-reducing
medicines. Participants’ breast cancer risk was estimated using tools based on the Gail Model. Trained personnel
examined all qualitative results systematically; risk perceptions and preferred method of medication delivery were
tallied quantitatively.
Results: Four focus groups (N = 32) were conducted. Most participants had at least a college degree (78.2 %) and
were of European (50 %) or African ancestry (31 %). The majority (72 %) were at elevated risk for breast cancer;
approximately half of these women perceived themselves to be at elevated risk. Few participants had prior knowledge
of preventive medications. The women noted a number of concerns about LTT, including dosage, impact on
day-to-day life, and side effects; nonetheless, over 90 % of the women stated they would prefer LTT to a pill.
Conclusion: Awareness of preventive medications was low even in a highly educated sample of high-risk
women. If given a choice in the route of administration, most women preferred a gel to a pill, anticipating
fewer side effects. Future work should focus on demonstrating equivalent efficacy and reduced toxicity of
topical over oral medications and on raising awareness of chemopreventive options for breast cancer.
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Background
Breast cancer is the most common cancer in women in
the United States, with more than 232,000 cases of inva-
sive cancer diagnosed in 2014 [1]. It is the second lead-
ing cause of cancer-related deaths among US women,
claiming over 40,000 lives each year [1]. Although mam-
mographic screening and advances in the treatment of
breast cancer have increased survival rates, primary pre-
vention of breast cancer remains a high priority since it
will allow women to avoid the trauma and toxicity of
cancer therapy, and eventually may also decrease breast
cancer death rates [1].
Selective estrogen receptor modulators (SERMs) pre-
scribed as preventive medications hold promise of redu-
cing the breast cancer burden. Tamoxifen, used for both
pre- and postmenopausal women, and a second orally
administered SERM, raloxifene, used in postmenopausal
women, are the only medications currently approved by
the FDA for use in the United States in the prevention
of breast cancer in women at increased risk for the dis-
ease [2]. In the Breast Cancer Prevention Trial (BCPT),
tamoxifen was shown to halve the incidence of invasive
breast cancer among high-risk women, and demon-
strated an even greater reduction in incidence of the dis-
ease among high-risk women with cellular atypia [3].
However, despite its well-documented benefits, tamoxi-
fen is associated with a number of risks and side effects,
including menopausal symptoms (hot flashes), venous
thrombo-embolism, cataracts, and increased risk for
endometrial cancer [4–6]. Because of these adverse effects,
tamoxifen is accepted by only 29–42 % of the women
offered the drug for chemoprevention [4, 7]. Moreover,
several studies have shown that the highest rates of
noncompliance are in younger women who would stand
to benefit the most from the medicine [8–10]. In addition,
among women who accept tamoxifen for chemopreven-
tion, 49 % interrupt or abandon therapy due to side effects
or fear of side effects [11]. Further, high-risk women who
are candidates for chemoprevention have indicated reluc-
tance to take a pill daily for five years, which is the current
mode of administration and recommended duration of
tamoxifen therapy [12, 13].
Delivering tamoxifen directly to the breast tissue via the
skin, i.e., local transdermal therapy (LTT), is a novel ap-
proach with anticipated advantages of reducing or possibly
eliminating systemic toxicities associated with oral therapies
and avoiding individual variations in drug metabolism that
could alter drug effectiveness. A small phase II study
demonstrated that an active metabolite of tamoxifen, 4-
Hydroxytamoxifen (4-OHT), applied to the skin of the
breast as a gel, reduced breast tumor cell proliferation
to the same extent as oral tamoxifen [14, 15]. We have
conducted two additional clinical studies to further test
the success of transdermal drug delivery to the breast.
In one study, we compared transdermal 4-OHT to oral
tamoxifen in a window trial of 26 women with ductal
carcinoma in situ (DCIS). Breast concentrations of 4-OHT
in the oral and transdermal groups were similar, with
equivalent suppression of cell proliferation (measured
as Ki-67 labeling) suggesting equivalent efficacy in DCIS
lesions, while the plasma concentration of 4-OHT was 5-
fold lower when compared to the oral tamoxifen group
[16]. This study confirmed that the gel formulation of an
active tamoxifen metabolite has the potential to perform
as well as the oral form of the medication with little
systemic exposure. In our second study, we randomized
30 women undergoing mastectomy to a diclofenac patch
applied either to the breast skin or the abdominal skin. Re-
sults indicated significantly higher concentrations of diclo-
fenac in breast tissue in those applying the patch directly
to their breast (manuscript accepted for publication).
These results showed that drugs applied to the breast skin
will preferentially concentrate in the parenchyma to a
greater degree than if applied to skin elsewhere, and that
biomarker endpoints suggest efficacy.
From this early experience, we conclude that topical
application of 4-OHT offers promise as an effective
preventive medication that women may find more ac-
ceptable than oral medication. As we continue efforts
to develop LTT for breast cancer prevention, we must
establish that these efforts will actually translate into
increased acceptance of this method of drug delivery
among at risk women. Therefore, we examined women’s
perceptions of preventive medicines and the acceptability
of a topical application of this active metabolite of tamoxi-
fen among a sample of high risk and average risk women
without a prior breast cancer diagnosis.
Methods
Eligibility
Because views of preventive medications may vary by a
women’s risk of developing breast cancer, we included
women at average and elevated risk of breast cancer. For
recruitment purposes, elevated risk was defined as risk
greater than that of the average-risk peer of the same
age or by virtue of possessing one or more of the follow-
ing conditions: a) a 1st or 2nd degree relative with breast
cancer diagnosed at any age; b) multiple prior breast bi-
opsies regardless of histology; c) prior or current evi-
dence of breast epithelial atypia (histologic or cytologic);
d) estimated mammographic density on visual inspection
of BIRADS 3 or 4; e) known carrier of BRCA 1 or 2 mu-
tation; and/or f ) prior history of chest wall radiation.
Women were considered average risk if they possessed
no more than one of the following characteristics: a) no
family history of breast cancer in a first or second degree
relative; b) one prior breast biopsy without atypia, and
c) BIRADS 1 or 2 estimated mammographic density
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on visual inspection. All participants were female age
21 or older.
Recruitment
Participants were identified through the Bluhm Family
Program for Breast Cancer Early Detection and Prevention
at Prentice Women’s Hospital, Lynn Sage Comprehensive
Breast Center. Eligible women received a phone call from
the study coordinator inviting them to participate in a focus
group about women’s views of their breast cancer risk and
methods to prevent breast cancer.
Focus groups
Focus groups were held in Prentice Women’s Hospital,
part of the Chicago campus of the Feinberg School of
Medicine of Northwestern University. An experienced
focus group moderator led consented participants through
a discussion of breast cancer risk perceptions and know-
ledge of and concerns about risk reduction medications.
Each woman was asked to characterize her own risk as
below average, average, or above average as part of the dis-
cussion. After discussing knowledge and concerns of risk
reduction medications, the moderator provided a brief
overview of LTT; the women then discussed their views of
the acceptability of a skin application of risk reduction
medication. Focus group sessions lasted approximately
60 min. The discussions were audiotaped and transcribed.
At the conclusion of the group, each participant completed
a short survey to provide sociodemographic information,
breast cancer risk factors (i.e., prior DCIS or LCIS diagno-
sis, menstrual and pregnancy history, family history of
breast cancer, number of prior breast biopsies, and prior
breast biopsies with atypical hyperplasia), and whether a
physician had ever suggested they take medication to re-
duce their breast cancer risk. At the completion of the
group, participants were given a handout providing infor-
mation on the two FDA approved medications currently in
use for breast cancer prevention. The moderator provided
information to participants at the end of the focus group
discussion, which addressed their questions. These included
the instructions for application, odor, and consistency.
Participants received $50 compensation for their time and
a voucher to cover parking expenses in a Northwestern
University parking structure. Following completion of the
focus groups, participants’ medical histories (biopsy his-
tory, BRCA status, breast density, and recommendations
to take preventive medications) were obtained via medical
record review. The Northwestern University Internal
Review Board approved all procedures.
Analysis
Focus group transcripts were content analyzed by the
first and last author. First, the number of women in each
group with prior knowledge of risk reduction medications
was tallied. Next, thematic analysis identified concerns
about preventive medicines and concerns about a topical
preventive medication. Concerns were identified and tal-
lied within and across groups. The analysts compared
their results and any differences were discussed and re-
solved. Each participant’s breast cancer risk was calculated
using the Breast Cancer Risk Assessment Tool provided
by the National Cancer Institute and the Detailed Breast
Cancer Risk Calculator created by Halls, both are based
on the Gail Model. Participants were classified as below,
at, or above the average risk for women of their age
[17, 18]. Participant survey responses and their perceived
risk were tallied.
Results
Four focus groups were conducted with 32 women. A
summary of participant sociodemographic characteris-
tics, breast cancer risk factors, and knowledge of pre-
ventive medications is shown in Table 1. The majority of
the sample was of European (50 %) or African ancestry
(31 %). Women ranged in age from 25 to 67 years. Des-
pite the high educational attainment of the group (94 %
of the participants attended college), less than 20% of
the women had any prior knowledge of preventive
medicines for breast cancer. Based upon our recruitment
criteria, 20 of the women were classified as high risk; 12
were classified as average risk. Table 1 shows the women’s
estimated breast cancer risk according to the Gail Model
for women over age 35 and Halls’ Model for those youn-
ger than 35 (N = 4). Twenty-three women were above peer
average, 3 were at the peer average, and 6 were below peer
average.
Perceived risk of breast cancer
When comparing women’s perceived breast cancer risk
with Gail Model estimates, women correctly assessed
their own personal risk 50 % of the time (Fig. 1).
Women overestimated their risk 21 % of the time and
underestimated their risk 29 % of the time. Notably, over
one third of women at increased risk for breast cancer
perceived themselves as average or below average risk.
One high-risk woman stated, “I would say (my risk) is
average ‘cause I choose to be positive. My sister passed
from breast cancer…which kind of made me a little, feel,
a little high risk…but my mother…she beat it…I’m hope-
ful, though.” Another high-risk woman said, “I consider
myself low risk because none of the women in my family
have ever had breast cancer, so I feel fortunate and not
that worried.”
When asked what drove their risk perceptions, women
most often cited family history. For example, one woman
who perceived herself as above average yet was calcu-
lated to be at average risk stated, “I think I have a greater
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risk because of a couple of factors, number one is family
history of breast cancer.” Other factors that shaped
women’s perceived risk included obesity, poor diet,
smoking, stress, environmental pollution/toxins, hormone
replacement therapy, nulliparity, breast augmentation, ab-
normal mammogram, dense breast tissue, history of breast
biopsy and genetic mutations.
Knowledge of preventive medications
Very few of the focus group participants were aware that
medications existed to prevent breast cancer. One woman
mentioned the drug Evista, stating that she knew “some
people use it for osteoporosis and they say it helps reduce
your risk for breast cancer, too.” Another woman admitted
that she had heard of tamoxifen but when asked what she
knew about the medication she stated, “There are some
not great side effects…I mean, it sounds a lot like meno-
pause.” Others who knew of tamoxifen were not aware of
its application to disease prevention and thought it was
only indicated for treatment of disease. “We hear a lot
about what’s going on in the research world and tamoxi-
fen…and just that it’s out there, but I don’t know anything,
specifics about reduction of rates, or side effects, or any-
thing like that.” Even those familiar with the medication
had limited knowledge of its purpose. By comparing
women’s focus groups comments about preventive medica-
tions with their risk perceptions, we ascertained that partic-
ipants who perceived themselves to be at high risk for
breast cancer tended to be more knowledgeable of prevent-
ive medications than those who did not perceive themselves
to be at elevated risk, 38 % vs 0 % respectively. Moreover,
women with awareness of preventive medications tended
to be older and had either a first-degree relative with the
disease or had undergone a breast biopsy.
Concerns about preventive medications
When prompted to list concerns they would have if their
doctor recommended that they take preventive medi-
cine, women in every group wanted to know about side
effects of the medicine. Further, women stated that they
would want their physician to give them an individual-
ized risk/benefit analysis and demonstrate that they
would see a significant risk reduction on the drug. A few
women voiced reluctance to the idea of taking medicine
for any indication and claimed that it would take a lot of
convincing and evidence provided to them by their
physician before they would consider accepting a drug.
Duration of therapy, interactions with other medications
or products, cost, and whether medicines used for pre-
vention would be covered by insurance were other major
concerns. Also, several women noted fears of taking
pills, and in some cases, difficulty swallowing them. The
following comments are representative of their concerns:
“I think the side effects are traumatizing relative to
what you’re treating. I mean just like incontinence
and like all this other stuff that comes up (from taking
various medications) that’s not even related to what
it’s treating…so you kind of wonder, why? Why would
you want to take this thing that could create these six
other problems?”
“Anything I have to take for something that I am
treating, I can deal with what I have to deal with, but
just as far as on the level of prophylactics, I would
want it to be pretty simple that way.”
Table 1 Focus Group participant demographics, breast cancer
risk, N = 32
Characteristic
Mean Age 48 (25–67)
Education
Some High School 2 (6 %)
Some College 5 (16 %)
College Degree 11 (34 %)
Graduate Degree 14 (44 %)
Ancestry
European 16 (50 %)
African 10 (31 %)
Other 6 (19 %)
Ethnicity
Hispanic 4 (13 %)
Non-Hispanic 28 (87 %)
Mean Age of Menarche 12 (9–17)
Mean Age at 1st Live Birth 29 (16–39)
1st or 2nd Degree Female Relative with Breast Cancer 21 (66 %)
History of Breast Biopsy 16 (50 %)
History of Biopsy with Atypia 3 (9 %)
BRCA 1/2 Mutation Carrier 0 (0 %)
BIRADS Mammographic Density
0 – No Mammogram 3 (9 %)
1 – Fatty 1 (3 %)
2 – Scattered Fibroglandular 9 (28 %)
3 – Heterogeneously Dense 19 (60 %)
4 – Extremely Dense 0 (0 %)
Prior Knowledge of Preventive Medicines 6 (19 %)
MD Recommended Preventive Medicine 2 (6 %)
Estimated Breast Cancer Risk (Gail Model)
Above Peer Average 23 (72 %)
At Peer Average 3 (9 %)
Below Peer Average 6 (19 %)
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“I’d like to know the risk benefit analysis on an
individual basis, what is the risk of not taking the
medicine versus the risk of taking the medicine. So
how elevated would my risk be for breast cancer if I
didn’t take it, and what are the benefits if I did take it,
and then look at the side effects.”
“I think probably the cost as well, I mean, don’t want
to send everybody to poor house… or myself trying to
prevent something”
“I’ve never been a pill person, so I’ve never wanted to,
I wouldn’t want to start anything that I’d have to
continue”
“I think that apart from the side effects, I would also
want to know the ease of taking the medicine, because I
hate taking pills and I gag and choke even when it’s a
tiny pill.”
Acceptability of skin application of tamoxifen
Although women had a number of reservations about
preventive medications, they were more open to the idea
of a gel application of the medicine. Over 90% of focus
group participants stated they would prefer the skin ap-
plication of preventive medicine over a pill application if
a physician advised them to take preventive medication
(Table 2). Of the remaining individuals, 6% were unsure
of which version they would prefer and would need
more information to make their decision, while one sub-
ject stated that she would prefer to take a pill. The most
common reason given for preferring a skin application
was a desire to avoid systemic side effects from a pill.
Other common reasons included a dislike of taking pills
and a preference for administering medication directly
to the site where it is needed. There was no correlation
Fig. 1 Perceived vs. Calculated Risk, Focus Group Participants, N = 28. The participants’ breast cancer risk was estimated using assessment calculators
based on the Gail Model. They were grouped according to their risk relative to that of their peer group as below, at, or elevated risk. 5 were calculated
to be below average risk. Among these women, 14 % of all participants, represented in blue, overestimated their risk, while 3.6 % correctly perceived
their risk as below average, represented in green. For the women calculated at peer average, 7 % overestimated their risk and 3.6 % correctly identified
their own risk, again shown in green. No one in this group underestimated their risk. Finally, in the high-risk group of 20 women, 43 % correctly
perceived themselves as high risk, green, while 29 % underestimated their risk, red. The total number of women that overestimated their risk
was 21 %, while 29 % underestimated their risk and 50 % correctly identified their own risk. 4 women who were unsure of their risk were excluded
from these data
Table 2 Focus Group participant willingness to use skin application of drug, N (%)
Which would you prefer for breast cancer prevention
if you were offered a choice between a pill and a gel?







Gel 11 (34 %) 15 (47 %) 3 (9 %) 29 (91 %)
Pill 0 (0 %) 1 (3 %) 0 (0 %) 1 (3 %)
Unsure 1 (3 %) 0 (0 %) 1 (3 %) 2 (6 %)
Total 12 16 4 32
aOnly two women perceived themselves as below average in risk of developing breast cancer and were therefore combined with those who perceived
themselves as average to simply the table
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between women’s risk perceptions and their preference
for or against the gel.
Concerns about skin application of tamoxifen
Focus group participants mentioned a number of concerns
they would want to discuss with their physician prior to
taking a topical preventive medication, including the im-
pact of the gel on day to day life, dosage, characteristics of
the gel, side effects, and whether the gel posed a threat to
others. Women in every group questioned whether they
could continue with normal activities (e.g., bathing, exer-
cising) while using the gel. They were also concerned
about the gel staining their clothes, whether they would
have to wait to get dressed after applying the gel, and how
soon after application they could bathe.
The women raised questions about the dosage of the
gel: How long would they take it? How much gel would
they apply each day? Does it need to be applied at the
same time each day? They questioned whether a gel could
be dosed properly, particularly given varying breast sizes
among women. In addition, they wanted to know more
about the characteristics of the gel, including its texture,
scent, packaging, and storage requirements.
Side effects were also a concern. The women wondered
about possible negative effects on hands, impact on organs
near the application site (e.g., lungs, heart), and changes to
the texture of the breast skin. One woman remarked, “I
would look at those side effects really, really carefully and
probably consult other doctors who could either put my
mind at rest or convince me not to take it.” A 45-year-old
woman who perceived her risk of breast cancer to be above
average said, “I mean I don’t know what the risks are,
but I would want to know the quality of life I would
have after taking that, you know, just for preventative,
in the event that there may not even be a chance that
I’d… develop breast cancer.” Likewise, women wondered
whether the gel posed a threat to others who touched it or
touched a woman’s skin after she used the gel. For ex-
ample, a participant questioned “Do you apply this with a
bare hand? Then it’s on my hand and I’m doing dishes or
cooking or putting a lunch together, you know, where
does, how is that transferring?” They were also concerned
about the impact of the gel on intimacy and on a woman’s
ability to breastfeed. Women also noted concerns about
cost and insurance coverage. One woman commented, “…
I don’t know if I’m going to be committed to buying a
pharmaceutical daily to prevent something that I may or
may not get, you know, but if it’s once a year and it’s in-
cluded in my health plan, and I don’t have to pay, you
know, a whole bunch for it.” A number of other concerns
were also mentioned, including interactions with other
lotions or foods/beverages a desire to see data to support
the gel’s efficacy.
Discussion and Conclusions
Our data, from a highly educated group of healthy women
at varying levels of perceived and calculated breast cancer
risk, demonstrate surprisingly low awareness of breast
cancer preventive medications. This was despite their high
educational attainment, adherence to screening and mo-
tivation to seek information about breast cancer detection
and prevention —100 % of the women over 40 had a
screening mammogram and 100 % of those younger than
40 had attended an appointment in the comprehensive
breast center to have a clinical breast exam and to learn
more about their own risk. We have evaluated, in a rigor-
ous and structured manner, the preference of this group for
the mode of delivery of preventive medications for breast
cancer. When preventive medications were described to
these women, 91 % of women expressed preference for a
skin application over an oral form. There was no relation-
ship between calculated or perceived breast cancer risk and
preference for the route of medication delivery. The num-
ber of women who accurately estimated their own risk,
50 %, was higher than most previously published studies,
which report frequent over-estimation of risk, especially
among women of European ancestry [19–21]. However,
60 % of high-risk women in our sample (excluding women
who were unsure of their risk) correctly perceived them-
selves to be high risk. This proportion is much higher than
findings from a recent publication in which as few as 18 %
of women calculated to be at high risk using the risk assess-
ment tools correctly perceived themselves to be at in-
creased risk for developing the disease [22]. Our subjects’
high level of education and adherence to screening recom-
mendations could account for the high number of women
who correctly assessed their risk.
Our findings also highlight information women would
want to know about skin applications of preventive med-
ications, including their impact on day-to-day life, dos-
age, characteristics of the medications, side effects, and
whether the topical medication posed a threat to others.
Notably, many of the women’s questions about the gel,
such as dosage and application, could be addressed via a
brief discussion with a physician or via product packaging.
Women also were concerned about the efficacy of a new
medication delivery method, cost, insurance coverage, and
determination of the population that would benefit most
from the medicine. The general consensus of this sample
of women was that if these concerns could be adequately
addressed then women would be more likely to accept a
medication for chemoprevention. Thus, a skin application
with limited systemic effects has the potential to gain ac-
ceptance among at risk women.
Our study has several limitations. The women’s prefer-
ences were based on hypothetical situations—women were
not actually confronted with the option of taking a pill or
gel for breast cancer prevention. Moreover, our results
Karavites et al. BMC Cancer  (2015) 15:878 Page 6 of 8
were based on a small sample of mostly well-educated
women from one large city. Each focus group expressed
many of the same concerns; thus we feel confident that we
have captured the most salient concerns for these women.
Only four women in our sample were under the age of 35,
the group where fertility concerns are an important issue,
and could be an influential factor in decisions regarding
preventive therapy for breast cancer. Future work should
examine how such concerns might impact the willingness
to take preventive medications. Additionally, work with
different populations of women may reveal other concerns
about preventive medications and LTT. Our sample repre-
sents women who may be most likely to take a preventive
medication because of their high risk status and overall at-
tention to their breast health, as evidenced by their regular
mammogram screening and use of clinical breast exams.
In addition, our sample, which has a mean age of 48, pro-
vides insights into the views of younger women towards
preventive medicine; this is particularly important as this
is the group least likely to accept preventive medications
[4]. These women, with long potential life expectancies,
stand to benefit most from preventive measures and are
the target population for chemopreventive agents [23].
Additional studies of the long-term efficacy of LTT are
needed and will increase women’s confidence in these novel
medications. In addition, increasing public awareness of
chemopreventive medications for breast cancer should be a
goal of public health initiatives to encourage acceptance of
preventive medications. Notably, the women in our study
were very interested learning more about the gel, including
when it would be available. Future work should also focus
on establishing the side effect reduction of topical 4-OHT
over oral tamoxifen. Because breast cancer chemopre-
vention requires a daily, long-term commitment from
women, it is not surprising that many women refuse or
stop taking the medication due to side effects and daily
burden [13, 24]. Even more worrisome, women already
facing the severity of a cancer diagnosis are discontinuing
these medicines before they achieve full benefit due to
these same concerns. The rates of adherence to oral adju-
vant endocrine therapy have been reported to be as low as
12–59 % in women with cancer, and are understandably
even lower in women taking the medicine for prevention
[4, 7, 8]. Attention must be paid to improving acceptance
and adherence to these drugs. For the healthy high risk
and DCIS populations, LTT offers a promising approach
to meeting this objective, which may in turn reduce the in-
cidence and burden of breast cancer.
As additional, larger studies of LTT are designed, it will
be important to address issues related to non-compliance
that have been identified in the therapeutic setting and may
apply to the prevention setting, regardless of the mode
of delivery. These include the presence of comorbidities,
negative mood prior to the initiation of endocrine therapy,
and greater perceived bother associated with multiple
symptoms [25–27]. Similarly, psychosocial characteristics
were identified in an epidemiologic review as the most
robust correlates of both non-adherence to therapy
(i.e., patient– oncologist relationship quality, perceived
need for endocrine therapy, endocrine therapy-related
negative emotions and depressive symptoms) [8]. Low
perceived financial status which has been shown to
apply to populations with both high and low incomes
[8, 27, 28]. Our group similarly voiced concerns over side
effects of preventive medications and did inquire about
the cost of a new medication and whether their insurance
provider would cover it. This will be an important param-
eter; particularly since transdermal formulations of many
drugs are often priced higher than oral formulations.
Comparing the concerns discussed in our focus groups to
those highlighted in previous studies illustrates the fact
that there are several reasons for low adherence to oral
tamoxifen. Addressing the concerns of at risk women and
removing the barriers they have identified should lead
to a boost in acceptance and compliance with preventive
medicines.
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